Cort
Phoenix Rising Founder
- Messages
- 7,392
(thanks to Tom Kindlon for providing this)
http://clinicaltrials.gov/ct2/show/NCT00598585
Use of Sildenafil to Alter Fatigue, Functional Status and Impaired Cerebral
Blood Flow in Patients With CFS
This study is currently recruiting participants.
Verified by Charles Drew University of Medicine and Science, February 2009
First Received: August 31, 2005
Last Updated: February 23, 2009
History of Changes
Sponsors and Collaborators: Charles Drew University of Medicine and Science
Pfizer
Information provided by: Charles Drew University of Medicine and Science
ClinicalTrials.gov Identifier: NCT00598585
Purpose
Use of Sildenafil to Alter Symptoms in Patients with Chronic Fatigue
Syndrome (CFS)
Condition Intervention Phase
Chronic Fatigue Syndrome
Drug: Sildenafil
Drug: Placebo
Phase IV
MedlinePlus related topics: Chronic Fatigue Syndrome
Drug Information available for: Sildenafil Sildenafil citrate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator),
Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Phase 4 Study of the Use of Sildenafil to Alter Fatigue,
Functional Status and Impaired Cerebral Blood Flow in Patients With Chronic
Fatigue Syndrome.
Further study details as provided by Charles Drew University of Medicine and
Science:
Primary Outcome Measures:
.The principal aim of this study is to determine whether chronic fatigue
syndrome (CFS) is due to inadequate blood flow to the brain and to test a
medication, Sildenafil, which should help increase blood flow to the brain
and improve the symptoms of CFS. [ Time Frame: 6 weeks ] [ Designated as
safety issue: Yes ]
Estimated Enrollment: 30
Study Start Date: July 2002
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date
for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Double Blind study- one group will be on Sildenafil and the other group will
be on placebo. Drug: Sildenafil
25 mg tid of either Sildenafil or Placebo for first week. 50 mg tid of
either Sildenafil or Placebo for second week. 100 mg tid of either
Sildenafil or Placebo for 3rd,4th, 5th and 6th week of study participation.
2: Placebo Comparator Drug: Placebo
Placebo
Detailed Description:
Use of Sildenafil to Alter Fatigue, Functional Status and Impaired Cerebral
Blood Flow in Patients with Chronic Fatigue Syndrome.
Eligibility
Ages Eligible for Study: 18 Years to 49 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes
Criteria
Inclusion Criteria:
.Patients meeting the CDC definition of CFS.
.All races, ethnicities, socio-economic status (SES), and gender
.Age greater than 18 (because of concerns about radioactivity, we and the
Cedars-Sinai and Harbor-UCLA IRBs have decided not to enroll subjects below
the age of 18).
.Age less than 50. Because of concern of sildenafil exacerbating coronary
artery disease, we will only enroll patients younger than 50.
.Able to provide informed consent.
.Willingness to be off all medicines and supplements for 3 weeks prior to
the study.
.Patients with psychiatric disorders (see below) will be included, if they
could be off their medications, and if their psychiatric diagnosis clearly
occurred after their fatigue symptoms began.
.Patients with concurrent fibromyalgia will be allowed to participate if the
meet diagnostic criteria for CFS.
Exclusion Criteria:
.Disabilities that would prevent them from participating in the study.
.Current use of prescription medicines (starting at 3 weeks prior to the
study) and supplements (starting at 1 weeks prior to the study) except
acetaminophen or aspirin. This includes herbal supplements and vitamins.
.Existing medical illnesses, such as heart disease, hypertension, cancer,
rheumatological diseases, endocrinopathies or hormone replacement therapy,
seizure disorders, severe obesity (BMI > 32 kg/m2),
.Severe psychiatric disorders including bipolar disorder, schizophrenia,
dementia and previous or current diagnosis of alcohol or substance abuse
within the past year. Patients with depression of such severity as to
warrant treatment with anti-depressants will be excluded.
.Current abuse of illicit drugs or heavy ethanol use.
.Pregnant women will be excluded because of radioactivity exposure from the
SPECT scans.
.Abnormal EKG
.Abnormal CBC, blood chemistries, thyroid function tests, and HIV, ANA, RF
and ESR tests.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00598585
Contacts
Contact: Erik Zuckerbraun, M.D. 310.668.8754 erikzuckerbraun@cdrewu.edu
Contact: Christian Gastelum, M.D. 310.668.8754 christiangastelum@cdrewu.edu
Locations
United States, California
Charles Drew University of Medicine and Science Recruiting
Los Angeles, California, United States, 90059
Contact: Erik Zuckerbraun, M.D. 310-668-8754 erzucker@cdrewu.edu
Contact: Christian Gastelum, M.D. 310.668.8754
Christiangastelum@cdrewu.edu
Principal Investigator: Ted C Friedman, M.D., Ph.D.
Sponsors and Collaborators
Charles Drew University of Medicine and Science
Pfizer
Investigators
Principal Investigator: Ted C Friedman, M.D., Ph.D. Charles Drew University
of Medicine and Science
More Information
Additional Information:
Clinical Trial Research site
No publications provided
Responsible Party: Charles Drew University of Medicine and Science (
Theodore C. Friedman, M.D.,Ph.D. principal investigator )
Study ID Numbers: 02-04-378-07
Study First Received: August 31, 2005
Last Updated: February 23, 2009
ClinicalTrials.gov Identifier: NCT00598585 History of Changes
Health Authority: United States: Institutional Review Board
Study placed in the following topic categories:
Vasodilator Agents
Fatigue
Central Nervous System Diseases
Encephalomyelitis
Sildenafil
Fatigue Syndrome, Chronic
Cardiovascular Agents
Virus Diseases
Signs and Symptoms
Phosphodiesterase Inhibitors
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Myalgic Encephalomyelitis
Additional relevant MeSH terms:
Vasodilator Agents
Fatigue
Disease
Molecular Mechanisms of Pharmacological Action
Nervous System Diseases
Central Nervous System Diseases
Enzyme Inhibitors
Sildenafil
Encephalomyelitis
Cardiovascular Agents
Fatigue Syndrome, Chronic
Pharmacologic Actions
Virus Diseases
Signs and Symptoms
Phosphodiesterase Inhibitors
Muscular Diseases
Pathologic Processes
Musculoskeletal Diseases
Neuromuscular Diseases
Therapeutic Uses
Syndrome
ClinicalTrials.gov processed this record on June 11, 2009
http://clinicaltrials.gov/ct2/show/NCT00598585
Use of Sildenafil to Alter Fatigue, Functional Status and Impaired Cerebral
Blood Flow in Patients With CFS
This study is currently recruiting participants.
Verified by Charles Drew University of Medicine and Science, February 2009
First Received: August 31, 2005
Last Updated: February 23, 2009
History of Changes
Sponsors and Collaborators: Charles Drew University of Medicine and Science
Pfizer
Information provided by: Charles Drew University of Medicine and Science
ClinicalTrials.gov Identifier: NCT00598585
Purpose
Use of Sildenafil to Alter Symptoms in Patients with Chronic Fatigue
Syndrome (CFS)
Condition Intervention Phase
Chronic Fatigue Syndrome
Drug: Sildenafil
Drug: Placebo
Phase IV
MedlinePlus related topics: Chronic Fatigue Syndrome
Drug Information available for: Sildenafil Sildenafil citrate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator),
Placebo Control, Parallel Assignment, Efficacy Study
Official Title: Phase 4 Study of the Use of Sildenafil to Alter Fatigue,
Functional Status and Impaired Cerebral Blood Flow in Patients With Chronic
Fatigue Syndrome.
Further study details as provided by Charles Drew University of Medicine and
Science:
Primary Outcome Measures:
.The principal aim of this study is to determine whether chronic fatigue
syndrome (CFS) is due to inadequate blood flow to the brain and to test a
medication, Sildenafil, which should help increase blood flow to the brain
and improve the symptoms of CFS. [ Time Frame: 6 weeks ] [ Designated as
safety issue: Yes ]
Estimated Enrollment: 30
Study Start Date: July 2002
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: December 2010 (Final data collection date
for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Double Blind study- one group will be on Sildenafil and the other group will
be on placebo. Drug: Sildenafil
25 mg tid of either Sildenafil or Placebo for first week. 50 mg tid of
either Sildenafil or Placebo for second week. 100 mg tid of either
Sildenafil or Placebo for 3rd,4th, 5th and 6th week of study participation.
2: Placebo Comparator Drug: Placebo
Placebo
Detailed Description:
Use of Sildenafil to Alter Fatigue, Functional Status and Impaired Cerebral
Blood Flow in Patients with Chronic Fatigue Syndrome.
Eligibility
Ages Eligible for Study: 18 Years to 49 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes
Criteria
Inclusion Criteria:
.Patients meeting the CDC definition of CFS.
.All races, ethnicities, socio-economic status (SES), and gender
.Age greater than 18 (because of concerns about radioactivity, we and the
Cedars-Sinai and Harbor-UCLA IRBs have decided not to enroll subjects below
the age of 18).
.Age less than 50. Because of concern of sildenafil exacerbating coronary
artery disease, we will only enroll patients younger than 50.
.Able to provide informed consent.
.Willingness to be off all medicines and supplements for 3 weeks prior to
the study.
.Patients with psychiatric disorders (see below) will be included, if they
could be off their medications, and if their psychiatric diagnosis clearly
occurred after their fatigue symptoms began.
.Patients with concurrent fibromyalgia will be allowed to participate if the
meet diagnostic criteria for CFS.
Exclusion Criteria:
.Disabilities that would prevent them from participating in the study.
.Current use of prescription medicines (starting at 3 weeks prior to the
study) and supplements (starting at 1 weeks prior to the study) except
acetaminophen or aspirin. This includes herbal supplements and vitamins.
.Existing medical illnesses, such as heart disease, hypertension, cancer,
rheumatological diseases, endocrinopathies or hormone replacement therapy,
seizure disorders, severe obesity (BMI > 32 kg/m2),
.Severe psychiatric disorders including bipolar disorder, schizophrenia,
dementia and previous or current diagnosis of alcohol or substance abuse
within the past year. Patients with depression of such severity as to
warrant treatment with anti-depressants will be excluded.
.Current abuse of illicit drugs or heavy ethanol use.
.Pregnant women will be excluded because of radioactivity exposure from the
SPECT scans.
.Abnormal EKG
.Abnormal CBC, blood chemistries, thyroid function tests, and HIV, ANA, RF
and ESR tests.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00598585
Contacts
Contact: Erik Zuckerbraun, M.D. 310.668.8754 erikzuckerbraun@cdrewu.edu
Contact: Christian Gastelum, M.D. 310.668.8754 christiangastelum@cdrewu.edu
Locations
United States, California
Charles Drew University of Medicine and Science Recruiting
Los Angeles, California, United States, 90059
Contact: Erik Zuckerbraun, M.D. 310-668-8754 erzucker@cdrewu.edu
Contact: Christian Gastelum, M.D. 310.668.8754
Christiangastelum@cdrewu.edu
Principal Investigator: Ted C Friedman, M.D., Ph.D.
Sponsors and Collaborators
Charles Drew University of Medicine and Science
Pfizer
Investigators
Principal Investigator: Ted C Friedman, M.D., Ph.D. Charles Drew University
of Medicine and Science
More Information
Additional Information:
Clinical Trial Research site
No publications provided
Responsible Party: Charles Drew University of Medicine and Science (
Theodore C. Friedman, M.D.,Ph.D. principal investigator )
Study ID Numbers: 02-04-378-07
Study First Received: August 31, 2005
Last Updated: February 23, 2009
ClinicalTrials.gov Identifier: NCT00598585 History of Changes
Health Authority: United States: Institutional Review Board
Study placed in the following topic categories:
Vasodilator Agents
Fatigue
Central Nervous System Diseases
Encephalomyelitis
Sildenafil
Fatigue Syndrome, Chronic
Cardiovascular Agents
Virus Diseases
Signs and Symptoms
Phosphodiesterase Inhibitors
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Myalgic Encephalomyelitis
Additional relevant MeSH terms:
Vasodilator Agents
Fatigue
Disease
Molecular Mechanisms of Pharmacological Action
Nervous System Diseases
Central Nervous System Diseases
Enzyme Inhibitors
Sildenafil
Encephalomyelitis
Cardiovascular Agents
Fatigue Syndrome, Chronic
Pharmacologic Actions
Virus Diseases
Signs and Symptoms
Phosphodiesterase Inhibitors
Muscular Diseases
Pathologic Processes
Musculoskeletal Diseases
Neuromuscular Diseases
Therapeutic Uses
Syndrome
ClinicalTrials.gov processed this record on June 11, 2009